Table 1.
Characteristics of included patients.
| D2 Group, No. (%) | D2 + No.10 Group, No. (%) | ||
|---|---|---|---|
| n=301 | n=432 | P | |
| Age, years | 0.545 | ||
| ≤60 | 118 (39.2%) | 179 (41.4%) | |
| >60 | 183 (60.8%) | 253 (58.6%) | |
| Sex | 0.093 | ||
| Male | 232 (77.1%) | 309 (71.5%) | |
| Female | 69 (22.9%) | 123 (28.5%) | |
| cT stage | 0.494 | ||
| ≤cT2 | 58 (19.3%) | 98 (22.7%) | |
| cT3 | 154 (51.2%) | 206 (47.7%) | |
| cT4 | 89 (29.6%) | 128 (29.6%) | |
| cN stage | 0.182 | ||
| cN0 | 81 (26.9%) | 136 (31.5%) | |
| cN+ | 220 (73.1%) | 296 (68.5%) | |
| Tumor size, cm | <0.001 | ||
| ≤5 | 163 (54.2%) | 301 (69.7%) | |
| >5 | 138 (45.8%) | 131 (30.3%) | |
| Histology | 0.207 | ||
| Differentiated | 106 (35.2%) | 172 (39.8%) | |
| Undifferentiated | 195 (64.8%) | 260 (60.2%) | |
| Cross-sectional part | 0.053 | ||
| Nongreater curvature | 282 (93.7%) | 387 (89.6%) | |
| Greater curvature | 19 (6.3%) | 45 (10.4%) | |
| Lymphovascular invasion | 0.096 | ||
| Absent | 169 (56.1%) | 269 (62.3%) | |
| Present | 132 (43.9%) | 163 (37.7%) | |
| Perineural invasion | 0.486 | ||
| Absent | 184 (61.1%) | 253 (58.6%) | |
| Present | 117 (38.9%) | 179 (41.4%) | |
| pT stage | 0.126 | ||
| T1 | 29 (9.6%) | 58 (13.4%) | |
| T2 | 25 (8.3%) | 37 (8.6%) | |
| T3 | 148 (49.2%) | 226 (52.3%) | |
| T4 | 99 (32.9%) | 111 (25.7%) | |
| pN stage | 0.001 | ||
| N0 | 65 (21.6%) | 134 (31.0%) | |
| N1 | 34 (11.3%) | 77 (17.8%) | |
| N2 | 82 (27.2%) | 82 (19.0%) | |
| N3a | 81 (26.9%) | 91 (21.1%) | |
| N3b | 39 (13.0%) | 48 (11.1%) | |
| pTNM stage | <0.001 | ||
| I | 41 (13.6%) | 72 (18.7%) | |
| II | 57 (18.9%) | 133 (30.8%) | |
| III | 203 (67.4%) | 227 (52.5%) | |
| Adjuvant chemotherapy | 0.589 | ||
| Absent | 104 (34.6%) | 141 (32.6%) | |
| Present | 197 (65.4%) | 291 (67.4%) |
LNs, lymph nodes.